Rescentris has raised additional funds through Series B sale of equity to further develop its range of ELN and scientific content management software for biology and multidisciplinary R&D equity. Investments were led by new and existing private investors, including leading scientists and inventors from Stanford University, former senior executives from Apple Computer and a major pharmaceutical company. Rescentris was also awarded $1m from Innovation Ohio Loan, as part of a State initiative to encourage Ohio businesses to create cutting-edge, innovative technologies.
This funding will support corporate growth, extension of industry-leading semantic data management technologies, release of the CERF Enterprise Edition and other new product offerings including distributed data management and archiving.
'The new funding, as well as the latest awards, demonstrate the confidence that our investors, the State of Ohio, and the global R&D community has in our team, the CERF technology, and growing ELN market opportunities,' stated Rescentris president Dr Jeff Spitzner. 'Growing numbers of life sciences – and increasingly other R&D organisations as well – are seeing our CERF platform as an insurance policy to protect their substantial investments in R&D and maximise returns.'
